Mar Vista Investment Partners LLC Has $29.15 Million Stock Position in Danaher Corporation (NYSE:DHR)

Mar Vista Investment Partners LLC reduced its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 2.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 142,189 shares of the conglomerate's stock after selling 3,133 shares during the quarter. Danaher comprises about 2.4% of Mar Vista Investment Partners LLC's investment portfolio, making the stock its 24th biggest position. Mar Vista Investment Partners LLC's holdings in Danaher were worth $29,149,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in the stock. Heck Capital Advisors LLC bought a new stake in Danaher in the fourth quarter worth $27,000. GHP Investment Advisors Inc. grew its holdings in Danaher by 396.0% during the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after purchasing an additional 99 shares during the last quarter. Sierra Ocean LLC grew its holdings in Danaher by 116.9% during the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after purchasing an additional 76 shares during the last quarter. Hurley Capital LLC bought a new position in Danaher during the 4th quarter valued at about $34,000. Finally, Smallwood Wealth Investment Management LLC bought a new stake in shares of Danaher during the 1st quarter worth approximately $31,000. 79.05% of the stock is owned by institutional investors.

Danaher Stock Performance

Shares of DHR stock traded down $0.71 during mid-day trading on Friday, reaching $204.80. The stock had a trading volume of 2,369,010 shares, compared to its average volume of 3,504,283. The firm has a market cap of $146.57 billion, a PE ratio of 39.77, a P/E/G ratio of 2.89 and a beta of 0.77. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.31. Danaher Corporation has a one year low of $171.00 and a one year high of $281.70. The firm's 50 day simple moving average is $195.94 and its 200 day simple moving average is $206.65.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, beating the consensus estimate of $1.62 by $0.26. Danaher had a net margin of 15.81% and a return on equity of 10.80%. The business had revenue of $5.74 billion for the quarter, compared to analysts' expectations of $5.58 billion. On average, analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.63%. Danaher's payout ratio is presently 24.85%.

Insider Activity

In other news, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the transaction, the chairman directly owned 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. This trade represents a 28.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Christopher Paul Riley sold 15,805 shares of the company's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the sale, the executive vice president owned 15,179 shares of the company's stock, valued at $3,005,442. The trade was a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 11.10% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on DHR. Wolfe Research decreased their price target on shares of Danaher from $275.00 to $220.00 and set an "outperform" rating for the company in a research note on Monday, April 7th. Evercore ISI dropped their price target on Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research report on Tuesday. Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target on the stock in a research report on Friday. Leerink Partners boosted their price target on shares of Danaher from $225.00 to $230.00 and gave the company an "outperform" rating in a report on Wednesday, April 23rd. Finally, The Goldman Sachs Group reduced their price target on shares of Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a report on Wednesday, April 23rd. Three research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. According to MarketBeat, Danaher has a consensus rating of "Moderate Buy" and an average target price of $248.43.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.